Nordic Nanovector Announces Presentation of Preclinical Data on Alpha37, at the American Association for Cancer Research 2022 Annual Meeting |
| March 09, 2022 | March 2022 Bond Updates |
|
OSLO, Norway, March 9, 2022 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANOV), a clinical-stage biotech company focused on CD37-targeted therapies for haematological cancers and immune diseases, announces that an E-poster regarding Alpha37, entitled "Targeted alpha therapy with... |
| View more at: https://www.prnewswire.com:443/news-releases/nordic-nanovector-announces-presentation-of-preclinical-data-on-alpha37-at-the-american-association-for-cancer-research-2022-annual-meeting-301498777.html |
| Related News |
|